These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 10077168)

  • 21. Cellular factors for resistance against antiretroviral agents.
    Fridland A; Connelly MC; Robbins BL
    Antivir Ther; 2000 Sep; 5(3):181-5. PubMed ID: 11075937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
    Mayers DL
    Am J Med; 1997 May; 102(5B):70-5. PubMed ID: 9845501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
    Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
    AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sustained high proportion of zidovudine-resistant HIV variants despite prolonged substitution of zidovudine by other nucleoside reverse transcriptase inhibitors.
    Bélec L; Legoff J; Si-Mohamed A; Andréoletti L; Mbopi-Kéou FX; Kolberg J; Matta M; Detmer J; Piketty C; Kazatchkine MD
    J Med Virol; 2002 Sep; 68(1):1-6. PubMed ID: 12210423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
    Venturi G; Romano L; Catucci M; Riccio ML; De Milito A; Gonnelli A; Rubino M; Valensin PE; Zazzi M
    Eur J Clin Microbiol Infect Dis; 1999 Apr; 18(4):274-82. PubMed ID: 10385016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.
    Chong KT; Pagano PJ
    Antiviral Res; 1997 Mar; 34(1):51-63. PubMed ID: 9107385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro.
    Saavedra-Lozano J; McCoig CC; Cao Y; Vitetta ES; Ramilo O
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2825-30. PubMed ID: 15273087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors.
    Balzarini J; De Clercq E; Carbonez A; Burt V; Kleim JP
    AIDS Res Hum Retroviruses; 2000 Apr; 16(6):517-28. PubMed ID: 10777142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased multinucleoside drug resistance and decreased replicative capacity of a human immunodeficiency virus type 1 variant with an 8-amino-Acid insert in the reverse transcriptase.
    van der Hoek L; Back N; Jebbink MF; de Ronde A; Bakker M; Jurriaans S; Reiss P; Parkin N; Berkhout B
    J Virol; 2005 Mar; 79(6):3536-43. PubMed ID: 15731248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies.
    Hillaireau H; Dereuddre-Bosquet N; Skanji R; Bekkara-Aounallah F; Caron J; Lepêtre S; Argote S; Bauduin L; Yousfi R; Rogez-Kreuz C; Desmaële D; Rousseau B; Gref R; Andrieux K; Clayette P; Couvreur P
    Biomaterials; 2013 Jul; 34(20):4831-8. PubMed ID: 23562054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
    J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.
    Schmit JC; Van Laethem K; Ruiz L; Hermans P; Sprecher S; Sönnerborg A; Leal M; Harrer T; Clotet B; Arendt V; Lissen E; Witvrouw M; Desmyter J; De Clercq E; Vandamme AM
    AIDS; 1998 Oct; 12(15):2007-15. PubMed ID: 9814869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
    Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
    J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
    Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
    J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anabolic steroid now available.
    AIDS Patient Care STDS; 1996 Apr; 10(2):134. PubMed ID: 11361700
    [No Abstract]   [Full Text] [Related]  

  • 36. Oxandrolone in AIDS-wasting myopathy.
    Berger JR; Pall L; Hall CD; Simpson DM; Berry PS; Dudley R
    AIDS; 1996 Dec; 10(14):1657-62. PubMed ID: 8970686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of testosterone in the AIDS wasting syndrome.
    Corcoran C; Grinspoon S
    AIDS Clin Care; 1999 Apr; 11(4):25-6, 33-4. PubMed ID: 11366208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-human immunodeficiency virus type 1 (HIV-1) activity of 2'-fluoro-2',3'-dideoxyarabinosyladenine (F-ddA) used in combination with other mechanistically diverse inhibitors of HIV-1 replication.
    Buckheit RW; Russell JD; Pallansch LA; Driscoll JS
    Antivir Chem Chemother; 1999 May; 10(3):115-9. PubMed ID: 10431610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential human immunodeficiency virus-suppressive activity of reverse transcription inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy.
    Davis C; Heredia A; Le N; Dominique JK; Redfield RR
    J Hum Virol; 2001; 4(3):113-22. PubMed ID: 11572234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro anti-HIV activity of oleanolic acid on infected human mononuclear cells.
    Mengoni F; Lichtner M; Battinelli L; Marzi M; Mastroianni CM; Vullo V; Mazzanti G
    Planta Med; 2002 Feb; 68(2):111-4. PubMed ID: 11859458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.